Pep talk
Consulting Room: Copper peptides are having a huge moment in skincare right now, but what does the evidence actually tell us about topical GHK-Cu? What benefits can we realistically say it may offer the skin?
Victoria Hiscock: The literature that’s currently available on copper peptides for skin is reassuringly consistent: fibroblast activation, type I collagen synthesis, GAG production, ECM remodelling, DEJ integrity and antioxidant activity are all on repeat. Ask any busy laser/peel/microneedling clinic and they’ll endorse this comfortably. Copper peptides have been used for decades in post-procedural care because they demonstrate meaningful activity across repair and remodelling pathways, and they have decades of safe cosmetic use behind them - well-formulated copper peptide products are beautifully tolerated and comforting on sensitised, compromised and post-procedural skin.
However, while the science behind what copper peptides can do on a cellular level is very exciting, translating that into measurable and visible results with an end formula is a very different quest. End-formulation human trials don’t yet support some of the claims coming through about what copper peptides can do on real skin – so we can’t yet say it’s the best thing since sliced retinoids.
CR: Where do copper peptides fit within an evidence-based skincare regime?
VH: At this moment in time, copper peptides don’t yet have main character energy in skincare. The industry isn’t offering a plethora of copper peptide-only formulas; instead, it’s smartly combined with other actives into multi-tasking, hybrid formulas. It sits symbiotically with established actives and contributes to a wider patient skincare journey across pre-and-post procedural care. But the evidence is exciting, so watch this space.
CR: Are there particular patients, skin concerns or stages of ageing where they may be especially useful?
VH: As the industry (rightly) re-categorises ageing as an inability to repair, an ingredient with a known track record for repairing has naturally evolved from the sensitive skin aisle and post-procedure arena and entered the longevity conversation. In the right formula, they could suit patients of all skin types and ages undergoing in-clinic procedures, using established actives, and on both preventative and corrective treatment plans.
Patients love the way these formulas feel. Soothing, calming, comfortable on skin that’s fragile and reactive, and protective at exactly the point the barrier needs supporting most. Comfort in the first 72 hours isn’t a soft benefit either. It drives compliance, it stops patients reaching for something unsuitable, and it shapes how they feel about the treatment they’ve just paid for.
CR: How do copper peptides compare with more established actives such as retinoids and vitamin C? Should we be thinking of them as an alternative, or as a complementary ingredient within a wider skin health strategy?
VH: Copper peptides complement established actives as part of a wider skincare routine and post-procedure recovery beautifully. It’s not yet possible to weigh them up as an alternative because the evidence bases aren’t comparable. Retinoids bring forty years of research, numerous randomised controlled trials, histology, biopsy data, dose-response curves, long-term safety and prescription status, all reinforced by decades of real-world clinical outcomes that consistently reflect what the data predicts. Copper peptides don’t, yet. Being a new(er) area of research isn’t a failing. It simply means the potential is still unknown.
They’re also employed for different biological benefit. Retinoids regulate epidermal turnover, keratinocyte differentiation, collagen metabolism and MMP inhibition. While there is some overlap, framing them as competitors misses what each is doing.
Vitamin C is a safe bet because we know its effective concentrations, optimal pH, stability requirements, penetration behaviour and clinical outcomes. We don’t know that with copper peptides yet.
CR: Not all copper peptide products are necessarily equal. How important are factors such as formulation, concentration, stability and delivery when assessing whether a product is likely to be effective, and what should practitioners be looking for when recommending one?
VH: As with any topical skincare ingredient and formula, dose and delivery are among the most important factors of all. GHK is small, hydrophilic and relatively unstable. How much survives the formulation, how much crosses the stratum corneum and how much remains biologically active on arrival at the target site will determine the outcome entirely.
The difficulty is that we don’t yet have robust data to answer any of those questions with confidence. A 2025 review asked whether we’re even equipped to measure the skin permeation of liposomal GHK-Cu, which tells you how early we still are.
So, while these factors matter enormously, they can’t yet function as a product selection filter. Until that evidence evolves, the more useful question is: what’s the end goal? Reduced post-procedural recovery? Better skin health? Improvement in the visible signs of ageing? Then create a checklist. What else is in the formula? How do those ingredients work synergistically? And what’s the evidence behind the finished formulation rather than the individual ingredient?
Ask these questions of the best post-procedure formulas on the market and they answer it well. They’re built around soothing, barrier support and recovery, with copper peptide contributing to that story rather than carrying it alone.
CR: With so much excitement around copper peptides at the moment, what expectations should practitioners be setting with patients? Where is the science genuinely exciting, and where is the marketing potentially running ahead of the evidence?
VH: Literature suggests that copper peptides demonstrate meaningful change at a cellular level, but therapeutic dose and delivery for clinically meaningful change aren’t yet established. That is exciting, because as vitamin C demonstrated, both are solvable.
But that’s also where marketing runs ahead. Biological activity is being presented as though it automatically equals visible clinical result. A mechanism can be well documented in a lab and still not have been shown to change what a patient sees in the mirror.
So, the expectation to set is an honest one. Copper peptides are a credible, well-tolerated contributor to skin quality and recovery, most valuable within a well-built formula rather than as a hero act.
The science is exciting because the biology holds up, but patience is required to see whether copper peptide first end-formulas eventually catch up. In the meantime, we already have formulas that make skin feel calm, comfortable and looked after when it needs it most, which is a very good place for an ingredient to be.